NCT03462446View on ClinicalTrials.gov

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

CompletedOBSERVATIONAL
Enrollment

249

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

May 1, 2016

Study Completion Date

May 1, 2016

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

DRUG

Vitamin K antagonists (VKAs)

As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.

Trial Locations (1)

Unknown

Granada

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY